At NUCLIDIUM we are developing a technology to produce novel diagnostic PET tracers that allow the imaging of different tumours and their metastases with great accuracy at an early stage of the disease. Our technology enables PET tracers to be widely accessible to commercial and academic PET scanning centres.
ENABLING BROAD ACCESS TO
PERSONALISED CANCER TREATMENT
Our vision is to enable broad access to personalised cancer
treatment, starting with early and accurate diagnosis
Learn more about us on our coming soon website!
For more information, contact us at info@nuclidium.com.